We are live on ! Find out more
DMKJ

David M. Knott Jr Portfolio holdings

AUM $168M
1-Year Est. Return 60.36%
This Fund
S&P 500
This Quarter Est. Return
+21.23%
1 Year Est. Return
+60.36%
3 Year Est. Return
+143.93%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$248M
AUM Growth
+$27.4M
Cap. Flow
-$3.33M
Cap. Flow %
-1.34%
Top 10 Hldgs %
69.93%
Holding
98
New
13
Increased
15
Reduced
10
Closed
10

Top Buys

Rank Stock Value
1
RZLT icon
Rezolute
RZLT
+$1.83M
2
PRAX icon
Praxis Precision Medicines
PRAX
+$1.36M
3
CYTK icon
Cytokinetics
CYTK
+$1.24M
4
SNDX icon
Syndax Pharmaceuticals
SNDX
+$985K
5
DAWN
Day One Biopharmaceuticals
DAWN
+$666K

Top Sells

Rank Stock Value
1
CLMT icon
Calumet Specialty Products
CLMT
+$7.4M
2
JAAA icon
Janus Henderson AAA CLO ETF
JAAA
+$2.91M
3
INZY
Inozyme Pharma
INZY
+$2.66M
4
ESGR
Enstar Group
ESGR
+$2.52M
5
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$2.5M

Sector Composition

Rank Sector Weight
1 Healthcare 34.94%
2 Materials 21.4%
3 Financials 15.49%
4 Communication Services 11.05%
5 Industrials 1.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RARE icon
26
Ultragenyx Pharmaceutical
RARE
$2.89B
$1.56M 0.63%
52,000
– –
PRAX icon
27
Praxis Precision Medicines
PRAX
$8.62B
$1.48M 0.6%
+28,000
New +$1.36M
RCUS icon
28
Arcus Biosciences
RCUS
$3.61B
$1.29M 0.52%
95,200
+25,200
+36% +$262K
JNJ icon
29
Johnson & Johnson
JNJ
$605B
$1.28M 0.52%
6,922
– –
CLOZ icon
30
Panagram BBB-B CLO ETF
CLOZ
$771M
$1.28M 0.52%
47,807
– –
BMY icon
31
Bristol-Myers Squibb
BMY
$124B
$1.22M 0.49%
27,000
– –
ABBV icon
32
AbbVie
ABBV
$450B
$1.17M 0.47%
5,037
– –
TECX
33
Tectonic Therapeutic
TECX
$599M
$1.16M 0.47%
74,000
– –
RHP icon
34
Ryman Hospitality Properties
RHP
$8.01B
$1.08M 0.43%
12,000
– –
SLDB icon
35
Solid Biosciences
SLDB
$841M
$1M 0.4%
162,440
– –
DAWN
36
DELISTED
Day One Biopharmaceuticals
DAWN
$920K 0.37%
130,500
+96,786
+287% +$666K
MDGL icon
37
Madrigal Pharmaceuticals
MDGL
$12.5B
$917K 0.37%
2,000
– –
MSFT icon
38
Microsoft
MSFT
$2.94T
$829K 0.33%
1,600
– –
HELP
39
Cybin Inc
HELP
$448M
$826K 0.33%
140,242
+73,362
+110% +$520K
VERA icon
40
Vera Therapeutics
VERA
$2.71B
$756K 0.3%
26,000
+6,000
+30% +$139K
CTVA icon
41
Corteva
CTVA
$58.4B
$747K 0.3%
11,051
– –
KMB icon
42
Kimberly-Clark
KMB
$36B
$746K 0.3%
6,000
– –
DD icon
43
DuPont de Nemours
DD
$18.4B
$734K 0.3%
7,503
– –
WVE icon
44
Wave Life Sciences
WVE
$1.12B
$659K 0.27%
90,000
+50,000
+125% +$405K
IBB icon
45
iShares Biotechnology ETF
IBB
$9.33B
$650K 0.26%
4,500
+2,500
+125% +$341K
AAPL icon
46
Apple
AAPL
$4.79T
$635K 0.26%
2,494
– –
MREO
47
Mereo BioPharma
MREO
$49.1M
$619K 0.25%
300,337
-19,000
-6% -$35K
IBM icon
48
IBM
IBM
$198B
$604K 0.24%
2,142
– –
KURA icon
49
Kura Oncology
KURA
$959M
$596K 0.24%
+67,302
New +$480K
ALKS icon
50
Alkermes
ALKS
$8.76B
$579K 0.23%
19,300
-29,700
-61% -$837K
1
2
3 4

Similar funds

DI
Disciplined Investors Waco, Texas $168M AUM 23.6% 1-Year Est. Return
WFS
Widmann Financial Services Bowie, Maryland $168M AUM 24.36% 1-Year Est. Return
CCG
Catalina Capital Group Torrance, California $168M AUM 16.69% 1-Year Est. Return
7CM
7G Capital Management New York $168M AUM 45.68% 1-Year Est. Return
TT
TI-Trust Quincy, Illinois $168M AUM 24.32% 1-Year Est. Return
MAG
Meadowbrook Advisors Group Bedminster, New Jersey $168M AUM
PFA
Presper Financial Architects Akron, Ohio $168M AUM 12.94% 1-Year Est. Return
CW
Code Waechter Tampa, Florida $168M AUM 15.56% 1-Year Est. Return

David M. Knott Jr's Q3 2025 Portfolio in Review

As of Q3 2025, David M. Knott Jr held 98 positions worth $248M, up 12% from $221M the previous quarter. Its ten largest holdings account for 70% of the portfolio.

David M. Knott Jr's Q3 2025 filing shows 13 new, 15 increased, 10 reduced and 10 closed positions. Its largest new stake was Rezolute: 275,000 shares worth $2.58M. The largest sale was Calumet Specialty Products, an estimated $7.4M.

By sector, the portfolio is most concentrated in Healthcare at 35% of assets, up from 31% a quarter earlier, followed by Materials and Financials.

  • David M. Knott Jr's largest Q3 2025 buy was Rezolute: 275,000 shares worth $2.58M.
  • David M. Knott Jr added most to Syndax Pharmaceuticals in Q3 2025, an estimated $985K increase.
  • David M. Knott Jr's biggest Q3 2025 reduction was Calumet Specialty Products, cutting an estimated $7.4M.
  • David M. Knott Jr fully exited Inozyme Pharma in Q3 2025, selling an estimated $2.66M.
  • David M. Knott Jr's ten largest holdings make up 70% of its $248M portfolio in Q3 2025.
  • David M. Knott Jr opened 13 new positions and closed 10 in Q3 2025.
  • David M. Knott Jr's portfolio value rose 12% quarter-over-quarter to $248M.

Based on David M. Knott Jr's 13F filing for Q3 2025, filed 12 Nov 2025.